cost-effectiveness analysis

Also found in: Dictionary, Thesaurus, Legal, Financial, Encyclopedia, Wikipedia.

cost-effectiveness analysis (CEA)

a type of economic evaluation used to determine the best use of money available for medical care. It compares different kinds of interventions with similar, but not identical, effects on the basis of the cost per unit achieved.

cost-effectiveness analysis

Cost-utility analysis Clinical trials A form of economic analysis in which alternative interventions are compared in terms of the cost per unit of clinical effect–eg cost per life saved, per mm Hg of lowered BP, per yr of quality-adjusted life gained, etc Health care policy Analysis related to the effectiveness of therapies or interventions and their associated costs. Cf Cost-benefit analysis.


pertaining to cost-effective.

cost-effectiveness analysis
a comparison of the relative cost-efficiencies of two or more ways of performing a task or achieving an objective.
References in periodicals archive ?
The cost-effectiveness analysis is justified as one of the most utilizes, because it is an economic analysis that results in different units of measure and additionally refers to both monetary resource as social benefits (Ministerio da Saude, 2008).
Cost-effectiveness analysis based on the number-needed-to-treat: common sense or non-sense?
The answers to these questions establish the degree to which a given cost-effectiveness analysis is even relevant for a given decision.
Economic evaluation and health care: cost-effectiveness analysis.
Cost-effectiveness analysis and weighted cost-effectiveness analysis can be used for comparing projects whose benefits are not readily measurable in monetary terms (Levin, 1983).
Cost-effectiveness analysis has won growing acceptance as a tool to help policymakers allocate health resources more effectively.
To help address the controversy that still simmers over how, or whether, to assign a specific value to effects such as degraded human health, OIRA and several federal agencies asked a committee of the National Academies' Institute of Medicine (IOM) to weigh in with guidance on one type of cost-benefit analysis, called cost-effectiveness analysis (CEA), which can include calculations of the dollar value of human life and which was included in Circular A-4.